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A B S T R A C T
Background: False-positives are a major concern in breast cancer screening. However, false-positives
have been little evaluated as a prognostic factor for cancer detection. Our aim was to evaluate the
association of false-positive results with the cancer detection risk in subsequent screening participations
over a 17-year period. Methods: This is a retrospective cohort study of 762,506 women aged 45–69 years,
with at least two screening participations, who underwent 2,594,146 screening mammograms from
1990 to 2006. Multilevel discrete-time hazard models were used to estimate the adjusted odds ratios
(OR) of breast cancer detection in subsequent screening participations in women with false-positive
results. Results: False-positives involving a ﬁne-needle aspiration cytology or a biopsy had a higher
cancer detection risk than those involving additional imaging procedures alone (OR = 2.69; 95%CI: 2.28–
3.16 and OR = 1.81; 95%CI: 1.70–1.94, respectively). The risk of cancer detection increased substantially
if women with cytology or biopsy had a familial history of breast cancer (OR = 4.64; 95%CI: 3.23–6.66).
Other factors associated with an increased cancer detection risk were age 65–69 years (OR = 1.84; 95%CI:
1.67–2.03), non-attendance at the previous screening invitation (OR = 1.26; 95%CI: 1.11–1.43), and
having undergone a previous benign biopsy outside the screening program (OR = 1.24; 95%CI: 1.13–
1.35). Conclusion: Women with a false-positive test have an increased risk of cancer detection in
subsequent screening participations, especially those with a false-positive result involving cytology or
biopsy. Understanding the factors behind this association could provide valuable information to increase
the effectiveness of breast cancer screening.
 2012 Elsevier Ltd. 
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One of the major concerns in breast cancer screening is the
false-positive result. The negative effects of a positive mammo-
graphic reading in which cancer is excluded after additional
evaluation include psychological [1] and behavioral consequences
to the screened women [2], as well as additional physician visits,
diagnostic tests, and excision biopsies [3,4].
The widespread adoption of breast cancer screening programs
involves screening thousands of women periodically, of whom a
large number will have a positive mammographic reading
requiring additional evaluation. The estimated proportion of* Corresponding author at: Department of Epidemiology and Evaluation, Mar
Teaching Hospital, 25-29 Passeig Marı´tim, 08003 Barcelona, Spain.
Tel.: +34 93 248 32 88; fax: +34 93 248 32 54.
E-mail address: xcastells@parcdesalutmar.cat (X. Castells).
1877-7821  2012 Elsevier Ltd. 
http://dx.doi.org/10.1016/j.canep.2012.10.004
Open access under CC BY-NC-ND license.women with a false-positive result after ten screening participa-
tions ranges from 20% to 32% in Europe [5–7] and around 49% in the
USA [8]. If the false-positive test involves cytology or a biopsy,
variability in the estimations increases substantially, ranging from
1.7% to 5% in Europe [5,7], and 18.6% in the USA [8]. However, a
negative result after additional evaluation does not necessarily
indicate the absence of a benign lesion or a suspicious mammo-
graphic pattern.
The dissemination of screening mammography has increased
the number of women with radiological abnormalities or benign
breast lesions, although there is no general agreement for the
follow-up of these women in the screening context. In most
population-based screening programs women with a false-positive
result follow the same screening recommendations as those with a
negative mammographic reading [9]. However, benign breast
lesions are a known risk factor for subsequent breast cancer
[10,11], and women with benign breast surgery have lower
sensitivity at screening [12]. Indeed, the presence of previous
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models assessing individual breast cancer risk, along with other
factors such as the use of hormone replacement therapy (HRT) and
a familial history of breast cancer [13–15].
Although several basic aspects of false positives and their
effects have previously been studied, the association between
false-positive results and detection of breast cancer in subsequent
screening participations has been little studied [16–20]. Most of
these studies had a small sample size and a short follow-up time, or
had no information on whether the false-positive result involved a
cytology examination or biopsy.
In the context of population-based screening programs, in
which large cohorts of women are sequentially invited for a
mammographic test over a time span of 20 years, the long-term
follow-up of women with false-positive results could enhance the
prediction of breast cancer risk [13,15]. This information might be
useful to improve the effectiveness of breast cancer screening
programs by encouraging women with false-positive results to
return for further screening.
The aim of this study was to evaluate the association of a false-
positive result with risk of breast cancer detection in a cohort of
screened women over a sequence of routine screening participa-
tions.
2. Methods
2.1. Setting and study population
The study sample was drawn from a retrospective cohort study
of screened women, conducted to evaluate the cumulative risk of a
false-positive result over ten sequential screening participations
[7]. Brieﬂy, all women aged 45–69 resident in Spain are actively
invited to participate in a population-based screening program
every 2 years. Population-based breast cancer screening in Spain
started in 1990 and became nationwide in 2006. Data from eight
regions, covering 44% of the Spanish target population, were
collected for this study. Each region has one or several radiology
units that perform screening [21]. Breast cancer screening in Spain
follows the European Guidelines for Quality Assurance in
Mammographic Screening [9].
Information was obtained from 945,789 women who had
undergone at least one screening mammogram between March
1990 and December 2006. These women underwent 2,777,429
screening mammograms in any of the 45 radiology units of the
eight participating regions that routinely collected information on
the women’s personal characteristics. The study was approved by
the Mar Teaching Hospital Research Ethics Committee.
2.2. False-positive results, cancer detection and women’s personal
characteristics
Women with a positive mammographic reading are recalled for
additional evaluation to exclude malignancy. The diagnostic work-
up took place within a maximum of 2 months after the screening
test. Some women with a probably benign result at mammo-
graphic reading are referred for an intermediate mammogram at 6
or 12 months before the interval corresponding to the normal
sequence (early recall) [22].
A positive result in the screening test was considered a false-
positive result if, after additional evaluation, breast cancer was not
diagnosed. Additional evaluation may include additional imaging
procedures (additional mammography, magnetic resonance imag-
ing, and ultrasonography), cytology (ﬁne-needle aspiration cytol-
ogy), or biopsy (core or open biopsy). A deﬁnitive diagnosis of
breast cancer was always histopathologically conﬁrmed (invasive
carcinoma or carcinoma ductal in situ). If cancer was excluded afteradditional evaluation, women were routinely invited to participate
in the screening program 2 years after the previous screening
invitation. No information was available on cancers diagnosed as
interval cancers or after women left the screening program.
Information on women’s characteristics was obtained by a face-
to-face interview performed by a trained health professional at the
time of each screening mammogram. This information included
the women’s age, HRT use (present use or in the previous 6
months), menopausal status (pre- or postmenopausal), previous
benign biopsy outside the screening program, and ﬁrst-degree
familial history of breast cancer.
2.3. Statistical analysis
The cancer detection rates were calculated as the number of
breast cancers detected at screening divided by the number of
screened women. The odds ratios (OR) and the 95% conﬁdence
intervals (95%CIs) for the association between false-positive
results and the risk of cancer detection in subsequent screening
participations were estimated with discrete time-hazard models.
These models use a logistic regression approach to compute these
particular survival models with discrete time intervals [23,24]. The
event of interest was whether or not cancer was detected at a
routine screening invitation. The probability of a cancer being
detected at a routine screening invitation (p(x)) was expressed as
ln(p(x)/1  p(x)) = ai Di + bj Xj, where p(x) is estimated by means
of the logit function, like any other logistic regression model. Di
corresponds to the time indicators: one for each woman’s
screening participation (ﬁrst screening, second screening, etc.).
Di equals 1 if the woman has performed her ith screening, and is 0
otherwise. The coefﬁcients of the time indicators are expressed by
ai and are the intercepts in the model (multiple intercept model).
As in any other regression model Xj is the jth study factor (i.e. ﬁrst-
degree familial history of breast cancer, attended previous
screening invitation, etc.), and bj is the estimated coefﬁcient for
the associated study factor. As cancers detected at ﬁrst screening
would not have a previous false-positive result in the screening
setting, ﬁrst screens were censored to compute the regression
model estimates, as they would underestimate the risk.
Simple and multivariate models were used to estimate the
individual and simultaneous effect of all predictors. The multivari-
ate models included the women’s personal variables (age, HRT use,
menopausal status, previous benign biopsy outside the screening
program, a ﬁrst-degree family history of breast cancer), whether or
not the woman attended her previous screening invitation, and the
presence of a false-positive result in any previous screening
participation. In addition, the multivariate models included a
period effect (calendar years), as the start date of the radiology
units differed, and a random effect component deﬁned by the
radiology units, because of the correlation among screening tests
performed in the same radiology unit. Residual pseudo-likelihood
estimation was used in all models by means of the GLIMMIX
procedure in SAS 9.1.2 (SAS Institute, Cary, NC).
In further analyses, we tested for interactions between false-
positive results and menopausal status, HRT use, family history of
breast cancer, and a previous benign biopsy outside the screening
program. For simplicity in the interpretation, we performed a
stratiﬁed analysis for those women’s characteristics showing a
statistically signiﬁcant interaction with false-positive results.
Besides, to study whether the number of screening rounds since
the false-positive test had an effect on the breast cancer risk, we
analyzed whether the false-positive test occurred in the previous
screening round (2 years) or two or more screenings in advance
(4 years).
Finally, we studied whether the cytologies and biopsies carried
out to exclude malignancy were associated with a differential
Table 2
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included the additional imaging procedures, cytologies, and
biopsies as independent categories.
3. Results
Of the 945,789 women who had undergone at least one
screening mammogram, we excluded information from 183,283
women (19.4%) who had participated in only one screening round
and could not be followed up over subsequent screening rounds.
We analyzed information from 762,506 women who had at least
two screening participations, who underwent 2,594,146 mammo-
graphic screening tests between 1990 and 2006. Average (standard
deviation) screening participations per woman was 3.70 (1.60);
73% of women had undergone three or more screening mammo-
grams, while 25.5% had at least ﬁve screenings.
Overall, the cancer detection rate in subsequent screenings
observed was 2.89 cases per 1000 screening mammograms (Table
1). The cancer detection rate for women with a previous false
positive involving an additional imaging procedure and those
involving a cytology or biopsy was 4.53 and 7.09 cases per 1000
screening mammograms, respectively. Other factors associated
with a higher detection rate were a ﬁrst-degree family history of
breast cancer, non-attendance at the previous screening invitation,
having experienced a benign biopsy outside the screening
program, older age, and post-menopausal status.
False positives showed an increased cancer detection risk in
subsequent screening participations. False positives involving aTable 1
Number of cancers detected and cancer detection rates in subsequent screens for




Cancers (N) Ratea (95%CI)
1,963,225 5670 2.89 (2.81–2.96)
Previous false-positiveb
Never 1,663,403 4256 2.56 (2.48–2.64)
Additional imaging 278,081 1261 4.53 (4.28–4.78)
Cytology or biopsy 21,588 153 7.09 (5.97–8.21)
Attended previous screening invitation
Yes 1,896,407 5410 2.85 (2.78–2.93)
No 66,818 260 3.89 (3.42–4.36)
Age (years)
45–49 177,671 333 1.87 (1.67–2.08)
50–54 467,619 1036 2.22 (2.08–2.35)
55–59 558,354 1569 2.81 (2.67–2.95)
60–64 514,556 1762 3.42 (3.26–3.58)
65–70 245,025 970 3.96 (3.71–4.21)
HRTc
No 1,743,323 5071 2.91 (2.83–2.99)
Yes 219,902 599 2.72 (2.51–2.94)
Menopausal status
Menopausal 1,656,585 5025 3.03 (2.95–3.12)
Premenopausal 306,640 645 2.10 (1.94–2.27)
First-degree family history of breast cancer
No 1,817,823 4989 2.74 (2.67–2.82)
Yes 145,402 681 4.68 (4.33–5.03)
Previous benign biopsy outside screening
No 1,826,679 5139 2.81 (2.74–2.89)
Yes 136,546 531 3.89 (3.56–4.22)
95%CI = 95% conﬁdence interval.
a Rate is presented as number of cancers per 1000 screening mammograms.
b Previous false-positive: at least one false-positive result in previous screening
rounds.
– Never: women who had never experienced a false-positive result.
– Additional imaging: a false-positive involving only an additional mammogram, or
a magnetic resonance imaging scan, or an ultrasound scan.
– Cytology or biopsy: a false positive involving ﬁne-needle aspiration cytology, or
core biopsy, or open biopsy. 95%CI = 95% conﬁdence interval.
c HRT: hormone replacement therapy use at the time of the mammogram or in
the previous 6 months.cytology or biopsy were associated with a signiﬁcantly higher risk
of cancer detection than false positives leading to additional
imaging procedures (OR = 2.69; 95%CI: 2.28–3.16 and OR = 1.81;
95%CI: 1.70–1.94, respectively) (Table 2). A higher cancer detection
risk was also observed in the oldest women (OR = 1.84; 95%CI:
1.67–2.03), women with a ﬁrst-degree familial history of breast
cancer (OR = 1.65; 95%CI: 1.52–1.79), those not attending the
previous screening invitation (OR = 1.26; 95%CI: 1.11–1.43), and
those with a previous benign biopsy outside the screening program
(OR = 1.24; 95%CI: 1.13–1.35). Of all the factors studied, a previous
false-positive result, independently of the additional procedure
involved (additional imaging, cytology or biopsy), showed the
highest risk of cancer detection (OR = 1.89; 95%CI: 1.77–2.01) (data
not shown).
The stratiﬁed analyses showed a stronger association of false
positives involving a cytology or biopsy with the risk of cancer
detection in women with a familial history of breast cancer
compared with that in women without a familial history of breast
cancer (OR = 4.64; 95%CI: 3.23–6.66, and OR = 2.41; 95%CI: 2.00–
2.89, respectively) (Table 3). No differences among women with a
familial history of breast cancer were observed for women with a
false positive involving additional imaging procedures. None of the
other women’s characteristics tested for an interaction showed a
statistically signiﬁcant difference.
Fig. 1 shows that false positives after additional imaging
procedures or after cytology or biopsy had an increased cancerEstimated odds ratios (OR) from the multiple regression model for the association
(non-adjusted and adjusted) between women’s characteristics and the risk of
cancer detection in subsequent screening participations.
Risk factor Subsequent
screens (N)
OR (95%CI) OR (95%CI)
Non-adjusteda Adjustedb
Previous false-positivec
Never 1,663,403 Ref Ref
Additional imaging 278,013 1.73 (1.62–1.85) 1.81 (1.70–1.94)
Cytology or biopsy 21,809 2.89 (2.48–3.37) 2.69 (2.28–3.16)
Attended previous screening invitation
Yes 1,896,407 Ref Ref
No 66,818 1.42 (1.25–1.61) 1.26 (1.11–1.43)
Age
45–49 177,671 0.83 (0.73–0.94) 0.83 (0.73–0.95)
50–54 467,619 Ref Ref
55–59 558,354 1.27 (1.18–1.38) 1.30 (1.20–1.42)
60–64 514,556 1.55 (1.43–1.68) 1.62 (1.49–1.77)
65–70 245,025 1.78 (1.63–1.95) 1.84 (1.67–2.03)
HRTd
No 1,743,323 Ref Ref
Yes 219,902 0.93 (0.86–1.02) 0.96 (0.88–1.04)
Menopausal status
Menopausal 1,656,585 Ref Ref
Premenopausal 306,640 0.71 (0.65–0.77) 0.92 (0.83–1.02)
First-degree family history of breast cancer
No 1,817,823 Ref Ref
Yes 145,402 1.69 (1.56–1.84) 1.65 (1.52–1.79)
Previous benign biopsy outside screening
No 1,826,679 Ref Ref
Yes 136,546 1.38 (1.26–1.51) 1.24 (1.13–1.35)
95%CI = 95% conﬁdence interval.
a Analysis adjusted by women’s screening participation.
b Multivariate analysis adjusted by women’s screening participation, screening
period (years), radiology unit (random effect), and all other factors in the table.
c Previous false-positive: at least one false-positive result in previous screening
rounds.
– Never: women who had never experienced a false-positive result.
– Additional imaging: a false-positive involving only an additional mammogram, or
a magnetic resonance imaging scan, or an ultrasound scan.
– Cytology or biopsy: a false positive involving ﬁne-needle aspiration cytology, or
core biopsy, or open biopsy.
d HRT: hormone replacement therapy use at the time of the mammogram or in
the previous 6 months.
Table 3
Estimated odds ratios (OR) from the multiple regression model for the association between false-positive results and subsequent breast cancer detection risk by the presence
or absence of a ﬁrst-degree familial history of breast cancer.
Previous false-positivea Women with a ﬁrst-degree family history of breast cancer Women without a ﬁrst-degree family history of breast cancer
Subsequent screens (N) Cancer (N) OR (95%CI) Subsequent screens (N) Cancer (N) OR (95%CI)
Adjustedb Adjustedb
Never 119,782 478 Ref 1,543,621 3778 Ref
Additional imaging 23,859 170 1.82 (1.51–2.18) 254,154 1091 1.81 (1.69–1.95)
Cytology or biopsy 17,961 33 4.64 (3.23–6.66) 20,048 120 2.41 (2.00–2.89)
a Previous false-positive: at least one false-positive result in previous screening rounds.
– Never: women who had never experienced a false-positive result.
– Additional imaging: a false-positive involving only an additional mammogram, or a magnetic resonance imaging scan, or an ultrasound scan.
– Cytology or biopsy: a false-positive involving ﬁne-needle aspiration cytology, or core biopsy, or open biopsy.
b Multivariate analysis adjusted by women’s screening participation, screening period (years), radiology unit (random effect), whether or not the woman attended the
previous screening invitation, age at screening, hormone replacement therapy use, menopausal status, and previous benign biopsy outside screening.
X. Castells et al. / Cancer Epidemiology 37 (2013) 85–9088detection risk, independently of whether the false-positive test
occurred in the previous screening round or two or more
screenings in advance. False-positive tests experienced in the
previous screening round were signiﬁcantly associated with a
higher cancer detection risk than those experiencing two or more
screenings in advance (P = 0.025 and P = 0.045, for false-positive
test after additional imaging procedures and after cytology or
biopsy, respectively).
The association between the type of additional procedure
carried out in the process leading to the false-positive test and the
cancer detection risk is shown in Fig. 2. No differences were found
in the cancer detection risk between false positives involving aFig. 1. Adjusted odds ratios (OR) for the cancer detection risk depending on whether
the false-positive test occurred in the previous screening round or two or more
screenings in advance.cytology and those involving a biopsy (OR = 2.95; 95%CI: 2.34–
3.71, and OR = 2.72; 95%CI: 2.11–3.52, respectively) (P = 0.90).
False positives leading to additional imaging procedures had a
signiﬁcantly lower cancer detection risk (OR = 1.75; 95%CI: 1.63–
1.88) than those involving cytology or a biopsy (P < 0.001 and
P = 0.005, respectively).
4. Discussion
We observed an increased risk of breast cancer detection in
women with a previous false-positive test in mammographic
screening. Women with a false positive involving cytology or biopsy
had a higher risk of cancer detection than those with a false positive
involving only an additional imaging procedure. This risk remained
signiﬁcantly higher 4 years or more after the false-positive test. The
cancer detection risk increased substantially if women with a
cytology or biopsy had a familial history of breast cancer.
The increased cancer detection risk in women with a false-
positive test observed in this study is in agreement with the results
of previous studies. In a recent study, Euler-Chelpin et al. found an
RR = 1.67 of breast cancer diagnosis after a false-positive test [16].
McCann et al. found an OR = 2.15 of cancer detection at the second
screen in women with a false-positive test at the ﬁrst screen [18].
A false-positive test in previous screening rounds is not in itself
a risk factor for breast cancer. Some authors have reported false
negatives in women undergoing additional evaluation after aFig. 2. Adjusted odds ratios (OR) for the cancer detection risk depending on the type
of additional procedure leading to the false-positive test.
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ment with the study of Euler-Chelpin et al., the cancer detection
risk remained signiﬁcantly higher 4 years or more after the false-
positive test [16]. Besides, cancers missed at additional evaluation
represent a small proportion of the whole [25], which could only
partially explain the association between false-positive tests and
the cancer detection risk in subsequent screening participations.
Women with a recommendation for additional evaluation are a
speciﬁc subgroup of women with mammographic abnormalities.
The absence of malignancy does not indicate the absence of benign
abnormalities, especially in women recalled for a cytology
examination or biopsy. A previous benign breast lesion is a known
breast cancer risk factor [10,11,28] and is commonly included in
models predicting breast cancer risk. However, few studies have
assessed the impact of previous benign lesions in the context of
breast cancer screening, in which non-symptomatic women are
routinely evaluated. In our analyses, false positives involving a
cytology examination or biopsy had an increased cancer detection
risk (OR = 2.95 and OR = 2.72, respectively) compared with
additional imaging procedures (OR = 1.75). This association was
stronger than any other factor analyzed in the study, most of which
are usually included in predictive models, such as a ﬁrst-degree
family history of breast cancer, older age, or a previous benign
biopsy outside screening.
The risk of cancer detection after a false-positive test involving a
cytology examination or biopsy was higher in women with a ﬁrst-
degree familial history of breast cancer (OR = 4.64). This differen-
tial effect could be partially explained by the presence of unknown
genetic factors or malignant precursors in these women, as well as
shared lifestyle and environment, which would involve prognostic
factors for benign breast disease to develop into a malignant lesion
[11]. In contrast with other studies [17], we found no signiﬁcant
differences in premenopausal women after adjusting for all the
other study factors.
We analyzed information from a wide retrospective cohort
over a 17-year period, which enabled us to ascertain the risk
over a series of sequential screening participations. The wide
spectrum of information analyzed – integrating information
from several radiology units with different screening protocols –
strengthens the consistency of the associations found, indepen-
dently of possible differences in screening practice or the period
analyzed. Moreover, the associations found were observed after
adjustment was made for possible confounders, and in the
stratiﬁed analysis. Nevertheless, our study also has some
limitations. We performed speciﬁc analyses to outline possible
causes for the association studied, which suggested some
possible underlying reasons. Further studies are required to
conﬁrm the suggested hypothesis. No information was available
on breast density, which could be associated with both an
increased false-positive risk and an increased breast cancer risk.
Previous studies have suggested that the association between
previous false positives and cancer detection is independent of
breast density [17].
The information provided in this study could be useful to
increase the effectiveness of breast cancer screening programs if
several surveillance strategies are rethought and deﬁned taking
into account personal factors related to breast cancer risk [29],
including the results of the screening test. Women with a false-
positive result should be encouraged to return for further
screening as they have an increased cancer detection risk, and a
decreased re-attendance probability [2]. Currently, the quality
guidelines [9] deﬁne the target population for screening only by
women’s age and include women who may have very different
breast cancer risks in the same target groups. In the actual debate
about the effectiveness of breast cancer screening it seems
straightforward to consider future screening strategies accordingto the breast cancer risk. Personalizing strategies would increase
the positive and negative predictive values of mammographic
screening, which in turn would enhance its effectiveness. Some
studies have provided evidence in this regard [29].
In conclusion, our results showed a strong association between
the presence of a false-positive test and the risk of cancer detection
in subsequent screening participations. The association was
stronger in false-positives involving a cytology examination or
biopsy, and in women with a family history of breast cancer.
Previous false-positive tests were a better predictor of cancer
detection in subsequent screens than older age, a previous benign
biopsy outside screening, or a family history of breast cancer alone.
In the context of mammographic screening, in which large cohorts
of women are assessed every 2 years, this personalized risk
information could be useful to improve the effectiveness of breast
cancer screening by emphasizing the need for return for further
screening in women with false-positive results.
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